BioMarin Stock Gaps Up On Today's Open (BMRN)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Shares of BioMarin Pharmaceuticals (Nasdaq: BMRN) were gapping up Monday morning with an open price 23% higher than Friday's closing price. The stock closed at $37.41 Friday and opened today's trading at $46.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

The average volume for BioMarin has been 1.4 million shares per day over the past 30 days. BioMarin has a market cap of $4.55 billion and is part of the health care sector and drugs industry. Shares are up 7% year to date as of the close of trading on Friday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. The company has a P/E ratio of -48.4, below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates BioMarin as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share. You can view the full BioMarin Ratings Report.

Get more investment ideas from our investment research center.

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.

null

More from Markets

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec

Dow Leads Major Indices With Triple-Digit Rally

Dow Leads Major Indices With Triple-Digit Rally